DK0415522T3 - Fremgangsmåde til reducering af krystalstørrelsen af ondansetron-hydrochlorid-dihydrat - Google Patents

Fremgangsmåde til reducering af krystalstørrelsen af ondansetron-hydrochlorid-dihydrat

Info

Publication number: DK0415522T3
Authority: DK; Denmark
Prior art keywords: reducing; hydrochloride dihydrate; ondansetron hydrochloride; crystal size; size
Prior art date: 1989-06-28

Application number

DK90307044.9T

Other languages

English (en)

Inventor

David Trevor Collin

Original Assignee

Glaxo Group Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1989-06-28

Filing date

1990-06-27

Publication date

1994-09-19

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10659180&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0415522(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1990-06-27 Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd

1994-09-19 Application granted granted Critical

1994-09-19 Publication of DK0415522T3 publication Critical patent/DK0415522T3/da

Links

FELGMEQIXOGIFQ-UHFFFAOYSA-N Ondansetron Chemical compound CC1=NC=CN1CC1C(=O)C(C=2C(=CC=CC=2)N2C)=C2CC1 FELGMEQIXOGIFQ-UHFFFAOYSA-N 0.000 title abstract 3
229960005343 ondansetron Drugs 0.000 title abstract 3
239000013078 crystal Substances 0.000 title abstract 2
238000000034 method Methods 0.000 title abstract 2
238000002425 crystallisation Methods 0.000 abstract 1
238000001035 drying Methods 0.000 abstract 1
239000000203 mixture Substances 0.000 abstract 1
239000002904 solvent Substances 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Hospice & Palliative Care (AREA)
Animal Behavior & Ethology (AREA)
Otolaryngology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Saccharide Compounds (AREA)
Medicinal Preparation (AREA)
Peptides Or Proteins (AREA)
Crystals, And After-Treatments Of Crystals (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Heterocyclic Compounds Containing Sulfur Atoms (AREA)
Glass Compositions (AREA)
Iron Core Of Rotating Electric Machines (AREA)

DK90307044.9T 1989-06-28 1990-06-27 Fremgangsmåde til reducering af krystalstørrelsen af ondansetron-hydrochlorid-dihydrat DK0415522T3 (da)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
GB898914804A GB8914804D0 (en)	1989-06-28	1989-06-28	Process

Publications (1)

Publication Number	Publication Date
DK0415522T3 true DK0415522T3 (da)	1994-09-19

Family

ID=10659180

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK90307044.9T DK0415522T3 (da)	1989-06-28	1990-06-27	Fremgangsmåde til reducering af krystalstørrelsen af ondansetron-hydrochlorid-dihydrat

Country Status (20)

Country	Link
US (1)	US5622720A (da)
EP (1)	EP0415522B1 (da)
JP (1)	JP3093242B2 (da)
KR (1)	KR0182789B1 (da)
AT (1)	ATE110380T1 (da)
AU (1)	AU637110B2 (da)
CA (1)	CA2019944C (da)
DE (1)	DE69011786T2 (da)
DK (1)	DK0415522T3 (da)
ES (1)	ES2060045T3 (da)
GB (1)	GB8914804D0 (da)
HK (1)	HK44495A (da)
HU (1)	HU208009B (da)
IE (1)	IE64715B1 (da)
IL (1)	IL94888A (da)
NZ (1)	NZ234267A (da)
RU (1)	RU2002745C1 (da)
SA (1)	SA90110025B1 (da)
UA (1)	UA18249A (da)
ZA (1)	ZA905002B (da)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9310756D0 (en) *	1993-05-25	1993-07-14	Glaxo Lab Sa	Compositions
GB9423511D0 (en) *	1994-11-22	1995-01-11	Glaxo Wellcome Inc	Compositions
RU2162695C1 (ru) *	2000-07-14	2001-02-10	ООО с иностранными инвестициями "Редди-Биомед лимитед"	Способ получения ондансетрона гидрохлорида дигидрата, субстанция и фармацевтический препарат
US20020115707A1 (en) *	2001-01-11	2002-08-22	Rami Lidor-Hadas	Process for preparing pure ondansetron hydrochloride dihydrate
RU2185825C1 (ru) *	2001-03-12	2002-07-27	Государственный научный центр - Институт биофизики	Фармацевтическая композиция, содержащая ондансетрон и метацин
CN100379723C (zh) *	2002-02-19	2008-04-09	特瓦制药工业有限公司	阿托伐他汀半钙脱溶剂的方法和基本上不含有机溶剂的阿托伐他汀半钙
EP1485344A1 (en)	2002-03-28	2004-12-15	Synthon B.V.	Venlafaxine besylate
PT1499623E (pt) *	2002-04-29	2007-08-10	Teva Gyogyszergyar Zartkoeruee	''processo papa a preparação de 1, 2, 3, 9-tetra-hidro-9-metil-3- [(2-metil-1h-imidazol-1-il) metil] -4h-carbazol-4-ona''
US20050131045A1 (en) *	2002-04-30	2005-06-16	Judith Aronhime	Novel crystal forms of ondansetron, processes for their preparation, pharmaceutical, compositions containing the novel forms and methods for treating nausea using them
US20060083759A1 (en) *	2002-07-17	2006-04-20	Aleksander Resman	Stabilization of the profile of release of active substances from a formulation
DE10393729T5 (de) *	2002-11-15	2005-10-13	Helsinn Healthcare S.A.	Verfahren zur Behandlung von Emesis
JO2735B1 (en) *	2003-01-30	2013-09-15	هيلسين هيلث كير أس ايه.	Liquid pharmaceutical formulations of palonosetron
US8598219B2 (en)	2003-01-30	2013-12-03	Helsinn Healthcare Sa	Liquid pharmaceutical formulations of palonosetron
TWI355936B (en) *	2003-02-18	2012-01-11	Helsinn Healthcare Sa	Uses of palonosetron hydrochloride
US7390503B1 (en)	2003-08-22	2008-06-24	Barr Laboratories, Inc.	Ondansetron orally disintegrating tablets
US20060167072A1 (en) *	2004-01-30	2006-07-27	Helsinn Healthcare Sa	Liquid pharmaceutical formulations of palonosetron
WO2005108392A2 (en)	2004-05-07	2005-11-17	Taro Pharmaceutical Industries Ltd.	Process for preparing ondansetron hydrochloride dihydrate having a defined particle size
WO2006091657A1 (en) *	2005-02-23	2006-08-31	Teva Pharmaceutical Industries, Ltd.	Rasagiline formulations of improved content uniformity
ZA200707469B (en) *	2005-02-23	2008-11-26	Teva Pharma	Rasagiline formulations of improved content uniformity
JP5769923B2 (ja)	2006-04-03	2015-08-26	テバファーマシューティカルインダストリーズリミティド	レストレスレッグス症候群の治療のためのラサギリンの使用
CN101573106B (zh) *	2006-10-24	2013-07-24	赫尔辛医疗股份公司	具有改进的稳定性和生物利用度的含帕洛司琼盐酸盐的软胶囊剂

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
LU88268I2 (da) *	1984-01-25	1994-02-03
US4695578A (en) *	1984-01-25	1987-09-22	Glaxo Group Limited	1,2,3,9-tetrahydro-3-imidazol-1-ylmethyl-4H-carbazol-4-ones, composition containing them, and method of using them to treat neuronal 5HT function disturbances
EP0275668B1 (en) *	1986-12-17	1992-09-30	Glaxo Group Limited	Use of ketone derivatives in the treatment of cognitive disorders
DK185489A (da) *	1988-04-22	1989-10-23	Duphar Int Res	Imidazolylmethyl-cycloalkanoebaaindoloner, deres fremstilling og anvendelse
US5344658A (en) *	1989-06-28	1994-09-06	Glaxo Group Limited	Process and composition using ondansetron

1989
- 1989-06-28 GB GB898914804A patent/GB8914804D0/en active Pending
1990
- 1990-06-27 CA CA002019944A patent/CA2019944C/en not_active Expired - Lifetime
- 1990-06-27 DK DK90307044.9T patent/DK0415522T3/da active
- 1990-06-27 DE DE69011786T patent/DE69011786T2/de not_active Expired - Lifetime
- 1990-06-27 AU AU57874/90A patent/AU637110B2/en not_active Expired
- 1990-06-27 HU HU904015A patent/HU208009B/hu unknown
- 1990-06-27 ES ES90307044T patent/ES2060045T3/es not_active Expired - Lifetime
- 1990-06-27 RU SU904830462A patent/RU2002745C1/ru active
- 1990-06-27 NZ NZ234267A patent/NZ234267A/en unknown
- 1990-06-27 KR KR1019900009540A patent/KR0182789B1/ko not_active Expired - Fee Related
- 1990-06-27 AT AT90307044T patent/ATE110380T1/de not_active IP Right Cessation
- 1990-06-27 EP EP90307044A patent/EP0415522B1/en not_active Expired - Lifetime
- 1990-06-27 JP JP02169655A patent/JP3093242B2/ja not_active Expired - Lifetime
- 1990-06-27 UA UA4830462A patent/UA18249A/uk unknown
- 1990-06-27 IE IE233390A patent/IE64715B1/en not_active IP Right Cessation
- 1990-06-27 IL IL9488890A patent/IL94888A/en unknown
- 1990-06-27 ZA ZA905002A patent/ZA905002B/xx unknown
- 1990-08-18 SA SA90110025A patent/SA90110025B1/ar unknown
1995
- 1995-03-23 HK HK44495A patent/HK44495A/en not_active IP Right Cessation
- 1995-06-07 US US08/472,881 patent/US5622720A/en not_active Expired - Lifetime

Also Published As

Publication number	Publication date
UA18249A (uk)	1997-12-25
JP3093242B2 (ja)	2000-10-03
SA90110025B1 (ar)	2001-03-24
HK44495A (en)	1995-03-31
AU5787490A (en)	1991-01-03
IL94888A0 (en)	1991-04-15
ES2060045T3 (es)	1994-11-16
EP0415522A1 (en)	1991-03-06
IL94888A (en)	1995-03-15
JPH0395178A (ja)	1991-04-19
HU904015D0 (en)	1990-12-28
CA2019944A1 (en)	1990-12-28
ATE110380T1 (de)	1994-09-15
NZ234267A (en)	1992-11-25
IE64715B1 (en)	1995-08-23
AU637110B2 (en)	1993-05-20
KR0182789B1 (ko)	1999-10-15
DE69011786T2 (de)	1994-12-15
KR910000709A (ko)	1991-01-30
RU2002745C1 (ru)	1993-11-15
IE902333L (en)	1990-12-28
HUT54140A (en)	1991-01-28
CA2019944C (en)	2000-05-09
DE69011786D1 (de)	1994-09-29
US5622720A (en)	1997-04-22
GB8914804D0 (en)	1989-08-16
IE902333A1 (en)	1991-01-16
HU208009B (en)	1993-07-28
EP0415522B1 (en)	1994-08-24
ZA905002B (en)	1991-12-24

Publication	Publication Date	Title
DK0415522T3 (da)	1994-09-19	Fremgangsmåde til reducering af krystalstørrelsen af ondansetron-hydrochlorid-dihydrat
FR2669635B1 (fr)	1994-06-10	Procede de fabrication d'hydroxymethylfurfural (hmf) du purete elevee.
PT73259B (en)	1983-06-28	Process for preparing novel substituted pyrazinyl-1,2,4-oxadiazole-5-ones
ES2023509B3 (es)	1992-01-16	Producto granular (i).
DE68917003D1 (de)	1994-09-01	Verfahren zur Herstellung von Halbleiterbauelementen, die gegen Musterverunreinigungen geschützt sind.
ZA922504B (en)	1993-12-07	Novel 2-spirocyclopropyl 4-acylcephems and processes for the preparation thereof
DK0508191T3 (da)	1996-07-01	Fremgangsmåde til fremstilling af 1-carbamoyl-pyrazoler
JPS5261287A (en)	1977-05-20	Preparation of pancreatic elastase
ZA918282B (en)	1992-07-29	Derivatives of(p.substituted phenyl)oxybutane amines,their processes of production and the pharmaceutical compositions containing them
NO905012D0 (no)	1990-11-20	Fremgangsmaate til fremstilling av cefemer, oksacefemer ogkarbacefemer og 3-sulfonyloksy-substituerte cefemer, oksacefemer og karbacefemer som utgangsprodukt ved fremgangsmaaten.
JPS51126841A (en)	1976-11-05	Reinforced light-fiber
JPS525700A (en)	1977-01-17	The process for production of silicon nitride
JPS52137944A (en)	1977-11-17	Time supervisory system of input output non-synchronous singnal
JPS53145517A (en)	1978-12-18	Video amplifier circuit
JPS51122095A (en)	1976-10-25	A process for preparing imidazobenzenediazepine derivatives
JPS53100562A (en)	1978-09-02	Apparatus for separating aligning disk-shaped articles
JPS51123064A (en)	1976-10-27	Forming process of bonding-pad area
JPS5225388A (en)	1977-02-25	Apparatus for changing the direction of goods being conveyed
JPS5277593A (en)	1977-06-30	Temperature compensating circuit of semiconductor strain meter
JPS5216779A (en)	1977-02-08	Total weight control system of conveyed articles
JPS522961A (en)	1977-01-11	Articles transfer conveyor
JPS5293787A (en)	1977-08-06	Novel process for preparation of cephem derivatives
JPS51120302A (en)	1976-10-21	Process for controlling turbine
DE3576498D1 (de)	1990-04-19	2-sulfamoyl-1h-indole-derivate zur behandlung von hohem intraocularem druck.
JPS53147186A (en)	1978-12-21	On off controller